Literature DB >> 12118396

Kidney and liver involvement in cryoglobulinemia.

Fabrizio Fabrizi1, Patrizia Colucci, Claudio Ponticelli, Francesco Locatelli.   

Abstract

Cryoglobulinemia is a pathological condition characterized by the presence in the blood of a group of proteins (cryoglobulins) showing the common property of precipitating from cooled serum. Mixed cryoglobulins (MCs) are composed of a polyclonal immunoglobulin G (IgG) bound to another immunoglobulin that acts as an anti-IgG rheumatoid factor; 2 types of MCs can be identified. The origin is not clear in 30% of all MCs, and this subset of cryoglobulinemias is called "essential." The great majority (up to 90%) of patients with essential MC (EMC) of both types has been related to HCV infection. The renal involvement in essential MC has been observed in 2% to 50% of patients in reported series. A well-characterized pattern of glomerular disease termed "cryoglobulinemic glomerulonephritis" is present in individuals with type-II EMCs in serum and IgMk RF being the most frequent monoclonal component. Aspecific and infrequent glomerular lesions occur in EMC patients with type III cryoglobulins. The most frequent histologic picture of cryoglobulinemic GN is that of membranoproliferative GN (MPGN) with subendothelial deposits. However, cryoglobulinemic GN may have some distinctive features that differentiate it from idiopathic type-I MPGN. Evidence of liver involvement has been found in 60% to 80% of EMC patients. Recent data support the notion that the stage of liver disease in patients with type II or III MC has association with the prevalence of cryoglobulinemia. Few controlled trials have been published on the treatment of HCV-related MC; in addition, the majority of the patients enrolled in these trials had an unclear renal involvement. Interferon (IFN) is an effective drug for the treatment of patients with HCV-associated MC and cryoglobulinemic GN. In the presence of acute cryoglobulinemic GN, IFN does not prevent progression of renal damage; combination therapy with cytotoxic ad anti-inflammatory drugs, and sometimes plasma exchange, is recommended. Prospective controlled trials are underway on this purpose. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12118396

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  13 in total

Review 1.  Management of hepatitis C in patients with chronic kidney disease.

Authors:  Mohammad A B Al-Freah; Zeino Zeino; Michael A Heneghan
Journal:  Curr Gastroenterol Rep       Date:  2012-02

Review 2.  HCV-negative mixed cryoglobulinemia and kidney involvement: in-depth review on physiopathological and histological bases.

Authors:  Leonardo Spatola; Elena Generali; Claudio Angelini; Salvatore Badalamenti; Carlo Selmi
Journal:  Clin Exp Med       Date:  2018-06-28       Impact factor: 3.984

3.  KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2018-09-19

4.  Hepatitis C virus and its renal manifestations: a review and update.

Authors:  Nyan Latt; Nada Alachkar; Ahmet Gurakar
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-07

Review 5.  Cryoglobulinaemic vasculitis: classification and clinical and therapeutic aspects.

Authors:  Gerald S Braun; Sophia Horster; Katrin S Wagner; Stephan Ihrler; Holger Schmid
Journal:  Postgrad Med J       Date:  2007-02       Impact factor: 2.401

Review 6.  Hepatitis C virus-associated extrahepatic manifestations: a review.

Authors:  Damien Sène; Nicolas Limal; Patrice Cacoub
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

7.  Hepatitis C infection and chronic renal diseases.

Authors:  Aline Gonzalez Vigani
Journal:  Hepatol Int       Date:  2012-03-15       Impact factor: 6.047

Review 8.  [Renal manifestations of rheumatic diseases].

Authors:  A Schwarting; E Märker-Hermann
Journal:  Z Rheumatol       Date:  2005-02       Impact factor: 1.372

Review 9.  Hepatitis C virus infection in nephrology patients.

Authors:  Lionel Rostaing; Jacques Izopet; Nassim Kamar
Journal:  J Nephropathol       Date:  2013-07-01

10.  TLR4 links podocytes with the innate immune system to mediate glomerular injury.

Authors:  Miriam C Banas; Bernhard Banas; Kelly L Hudkins; Tomasz A Wietecha; Masayuki Iyoda; Elisabeth Bock; Peter Hauser; Jeffrey W Pippin; Stuart J Shankland; Kelly D Smith; Benjamin Stoelcker; Gang Liu; Hermann-Josef Gröne; Bernhard K Krämer; Charles E Alpers
Journal:  J Am Soc Nephrol       Date:  2008-02-06       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.